Octaplas
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Octaplas
- Generic name
- HUMAN PLASMA PROTEINS
- Manufacturer
- Octapharma USA Inc
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 32e71c00-2953-73eb-974e-dd5be6c9f00f
- SPL ID
- ffbb7ae1-5bc6-ce20-c70d-80b8453f34d3
- Version
- 25
- Effective date
- 2024-10-02
- Source export date
- 2026-11-13
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:35:49
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125416 | derived:openfda.application_number |
| application number | BLA125416 | openfda.application_number | |
| brand name | Octaplas | openfda.brand_name | |
| generic name | HUMAN PLASMA PROTEINS | openfda.generic_name | |
| manufacturer name | Octapharma USA Inc | openfda.manufacturer_name | |
| ndc | package | 68982-954-01 | openfda.package_ndc |
| ndc | product | 68982-954 | openfda.product_ndc |
| ndc11 | package | 68982095401 | derived:openfda.package_ndc |
| spl id | ffbb7ae1-5bc6-ce20-c70d-80b8453f34d3 | id | |
| spl set id | 32e71c00-2953-73eb-974e-dd5be6c9f00f | set_id | |
| unii | 6D53G0FD0Z | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Transfusion reactions can occur with ABO blood group mismatch ( 5.1 ) High infusion rates can induce hypervolemia with consequent pulmonary edema or heart failure ( 5.2 ) Excessive bleeding due to hyperfibrinolysis can occur due to low levels of alpha 2-antiplasmin ( 5.3 ) Thrombosis can occur due to low levels of Protein S ( 5.4 ) Citrate toxicity can occur with volumes exceeding one milliliter of Octaplas per kg per minute ( 5.5 ) Octaplas is made from human blood and may carry the risk of transmitting infectious agents, e.g., viruses and theoretically, the variant Creutzfeldt-Jakob disease and Creutzfeldt-Jakob disease agent ( 5.6 ) 5.1 Transfusion reactions Transfusion reactions can occur with ABO blood group mismatches. Administration of Octaplas must be based on ABO-blood group compatibility. 5.2 Hypervolemia High infusion rates can induce hypervolemia with consequent pulmonary edema or heart failure. Monitor patients for signs and symptoms of pulmonary edema or heart failure and institute appropriate management. 5.3 Hyperfibrinolysis Excessive bleeding due to hyperfibrinolysis can occur due to low levels of alpha 2-antiplasmin. Monitor for signs of excessive bleeding in patients undergoing liver transplantation. 5.4 Thrombosis Thrombosis can occur due to low levels of Protein S. Monitor for signs and symptoms of thrombosis in patients at risk. 5.5 Citrate Toxicity Citrate toxicity can occur with volumes exceeding one milliliter of Octaplas per kg per minute. The infusion rate should not exceed 0.020-0.025 mmol citrate per kilogram per minute (i.e., less than one milliliter Octaplas per kg per minute). Symptoms attributable to citrate toxicity (hypocalcemia) include fatigue, paresthesia and muscle spasms, especially in patients with liver function disorders. Administer calcium gluconate intravenously into another vein in order to minimize citrate toxicity. 5.6 Infection Risk from Human Plasma Because Octaplas is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ALL infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Octapharma [1-866-766-4860] or FDA at 1-800-FDA-1088 or www.fea.gov/medwatch. See Description ( 11 )
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Serious adverse reactions seen in clinical trials were anaphylactic shock, citrate toxicity and severe hypotension. The most common adverse reactions observed in ≥ 1% of subjects included pruritis, urticaria, nausea, headache and paresthesia. The most common adverse reactions observed in ≥ 1% of patients included pruritis, urticaria, nausea, headache, paresthesia. ( 6 ). Serious adverse reactions seen in clinical trials were anaphylactic shock, citrate toxicity and hypotension. To report SUSPECTED ADVERSE REACTIONS, contact Octapharma USA Inc. at phone # 866-766-4860 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect rates observed in clinical practice. Adverse reactions observed in clinical trials derive from 9 clinical trials. The mean dose administered ranged from 6 to 15 milliliters/kg body weight; when used in plasma exchange the dose was between 15 to 75 milliliters/kg. Two of the studies were conducted in healthy volunteers (n=90). In total, 359 subjects received about 600 transfusion episodes in these trials. The following table shows the adverse reactions observed in ≥ 1% of subjects in order of severity: Nervous system disorders Headache, paresthesia Gastrointestinal disorders Nausea Skin and subcutaneous tissue disorders Pruritis, urticaria 6.2 Postmarketing Experience Because post-marketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. Blood system disorders Hyperfibrinolysis Immune system disorders Hypersensitivity reactions including anaphylactoid and allergic type of reactions Metabolic and nutritional disorders Alkalosis Cardiovascular disorders Cardiac arrest, circulatory overload, thromboembolism, tachycardia Respiratory, thoracic and mediastinal disorders Respiratory arrest or failure, bronchospasm, pulmonary edema, dyspnea, tachypnea, transfusion-related acute lung injury (TRALI) Gastrointestinal disorders Abdominal pain, vomiting Skin and subcutaneous tissue disorders Rash, erythema General disorders and administration site conditions Fever and/or chills, chest discomfort or pain Investigations Seroconversions (passive transfer of antibodies); passive transmission of analytes, e.g. β-human chorionic gonadotropin [ 3 ] Injury, poisoning and procedural complications Citrate toxicity
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Nervous system disorders</content></content> Headache, paresthesia</td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Gastrointestinal disorders</content></content> Nausea</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Skin and subcutaneous tissue disorders</content></content> Pruritis, urticaria</td></tr></tbody></table>
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Blood system disorders</content></content> Hyperfibrinolysis</td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Immune system disorders</content></content> Hypersensitivity reactions including anaphylactoid and allergic type of reactions</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Metabolic and nutritional disorders</content></content> Alkalosis</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Cardiovascular disorders</content></content> Cardiac arrest, circulatory overload, thromboembolism, tachycardia</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Respiratory, thoracic and mediastinal disorders</content></content> Respiratory arrest or failure, bronchospasm, pulmonary edema, dyspnea, tachypnea, transfusion-related acute lung injury (TRALI)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Gastrointestinal disorders</content></content> Abdominal pain, vomiting</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Skin and subcutaneous tissue disorders</content></content> Rash, erythema</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> General disorders and administration site conditions</content></content> Fever and/or chills, chest discomfort or pain</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Investigations</content></content> Seroconversions (passive transfer of antibodies); passive transmission of analytes, e.g. β-human chorionic gonadotropin [<linkHtml href="#REFERENCES"> 3</linkHtml> ]</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"><content styleCode="italics"> Injury, poisoning and procedural complications</content></content> Citrate toxicity</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.